Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Basal Cell Carcinoma (BCC) Clinical Trial

Official title:

A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02144077
• Other study ID #: ALA-BCC-CT008
• Secondary ID: 2013-003241-42
• Status: Completed
• Phase: Phase 3
• Start date: January 28, 2014
• Est. completion date: September 9, 2020

Study information

• Verified date: October 2022
• Source: Biofrontera Bioscience GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).

Description:

The treatment comprises of up to 2 PDT cycles, each with two PDT sessions one week apart.

If 12 weeks after the the second PDT all lesions are completely cleared the patient will enter the follow-up phase. In case of remaining lesions the patient will receive a second PDT cycle starting on the same day.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 281
• Est. completion date: September 9, 2020
• Est. primary completion date: November 17, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Main Inclusion Criteria:

• Willing and able to sign informed consent form; obtained in writing before starting any study procedures

• Presence of 1-3 thin (=2 mm thickness), clinically non-aggressive, primary BCC lesions (primary superficial, nodular, or mixed superficial/nodular) in the face/forehead, bald scalp, extremities and/or neck/trunk. Confirmation of non-aggressiveness and thickness of BCC through biopsies taken at screening for at least one lesion. Lesions non-eligible according to biopsy should timely be removed by surgery or cryotherapy

• Diameters of lesions should range between =0.5cm and =2cm; total maximal treated area is 10cm² (including 0.5-1.0cm margin surrounding each lesion)

• Target BCC lesions must be discrete and quantifiable and have to be located within 1-2 treatment areas

• Free of significant physical abnormalities (eg tattoos, dermatoses) in potential treatment area that may cause difficulty with examination or final evaluation

• Accept to abstain from extensive sunbathing and use of solarium during observer blind part. Patients with sunburn within treatment areas cannot be included until fully recovered

• Healthy patients and patients with clinically stable medical conditions, including, but not limited to controlled hypertension, diabetes mellitus type II, hypercholesterolemia, and osteoarthritis, will be permitted to be included in study if their medication is not prohibited by protocol

• Women of childbearing potential are permitted to participate in study only if they have a negative serum pregnancy test at screening and willingness to use a highly effective method of contraception during observer blind part

Main Exclusion Criteria:

• History of hypersensitivity to 5-ALA or any ingredient of BF-200 ALA, MAL or any ingredient of Metvix®, including arachis oil, or to peanut or soya

• Hypersensitivity to porphyrins

• Current treatment with immunosuppression therapy

• Presence of porphyria

• Presence of BCC lesions on embryonic fusion planes (H-zone)

• Presence of more than 3 BCCs

• Presence of malignant or benign tumors of the skin other than non-aggressive BCC within the treatment area (eg malignant melanoma, squamous cell carcinoma (SCC), aggressive BCC clinically diagnosed at screening) within the last 12 weeks

• Gorlin Syndrome or Xeroderma pigmentosum

• Presence of photodermatoses

• Treatment of lesions (actinic keratosis (AK), BCC, SCC, Bowens disease, melanoma) =12 weeks prior to first PDT, except physical treatments (eg cryosurgery, excision surgery) that will not be allowed =6 weeks prior to first PDT (Visit 2). Lesion(s) that seemed eligible clinically which could not be confirmed by biopsy, and which are located =10cm to an eligible lesion should timely be removed physically only

• Presence of inherited or acquired coagulation defect

• Start of intake of medication with hypericin or systemically-acting drugs with phototoxic or photoallergic potential within 8 weeks prior to screening

• Clinically relevant cardiovascular, hepatic, renal, neurologic, endocrine, or other major systemic disease making implementation of protocol or interpretation of study results difficult

• Evidence of clinically significant (CS), unstable medical conditions, eg:

• Metastatic tumor or tumor with high probability of metastasis

• Cardiovascular disease (New York Heart Association [NYHA] class III, IV)

• Immunosuppressive condition

• Hematologic, hepatic, renal, neurologic, or endocrine condition

• Collagen-vascular condition

• Gastrointestinal condition

• Topical treatment with 5-ALA or MAL outside treatment area during the observer blind part

• Any topical treatment including diclofenac and immunomodulatory agents (eg imiquimod, ingenol mebutate) 12 weeks prior to first PDT session and during observer blind part

• Any physical treatment during the observer blind part within treated target areas with exception of lesion(s) determined non-eligible by biopsy

Related Conditions & MeSH terms

• Basal Cell Carcinoma (BCC)
• Carcinoma
• Carcinoma, Basal Cell

Intervention

Drug:
• BF-200 ALA
Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
• methyl-aminolevulinate
Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)

Locations

Country	Name	City	State
Germany	Klinikum Vest GmbH	Recklinghausen	Westfalen-Lippe

Sponsors (2)

Lead Sponsor	Collaborator
Biofrontera Bioscience GmbH	Accovion GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Morton CA, Dominicus R, Radny P, Dirschka T, Hauschild A, Reinhold U, Aschoff R, Ulrich M, Keohane S, Ekanayake-Bohlig S, Ibbotson S, Ostendorf R, Berking C, Gröne D, Schulze HJ, Ockenfels HM, Jasnoch V, Kurzen H, Sebastian M, Stege H, Staubach P, Gupta G — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patient Recurrence Rate (Overall, Cumulative)	Patient recurrence rate defined as the number of patients with at least one recurrent lesion during FU after complete clearance 12 weeks after the last PDT	6, 12, 24, 36 and 60 months post-PDT
Other	Lesion Recurrence Rate (Cumulative)	Lesion recurrence rate defined as the number of completely cleared lesions 12 weeks after the last PDT showing recurrence during FU. Overall and subgroup analysis (nodular basal cell carcinoma (nBCC) and superficial basal cell carcinoma (sBCC)).	6, 12, 24, 36 and 60 months post-PDT
Primary	Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT	Overall patient complete response rate assessed 12 weeks after the last PDT. The indicated values give the percentage of overall complete responders. An overall complete responder is defined as a patient in whom all treated lesions were cleared. The PP set is the primary analysis set for the analyses of the primary endpoint.	12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Secondary	Lesion Complete Response Assessed 12 Weeks After the Last PDT	Lesion complete response (completely cleared individual lesions) assessed 12 weeks after the last PDT. The indicated values give percentage of overall completely cleared individual lesions. The PP set is the primary analysis set for the analysis of the secondary endpoint.	12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Secondary	Reduction of Lesion Area 12 Weeks After the Last PDT Compared to Baseline	Reduction of total lesion area (summation of sizes of all treated lesions) per patient, assessed 12 weeks after the last PDT. The PP set is the primary analysis set for the analysis of the secondary endpoint.; Please note that the high SD for BF-200 ALA is due to a patient who had increased lesion area fom 63 mm² at baseline to 225 mm² 12 weeks after PDT. This lesion area included a lesion that was later confirmed to be benign skin condition (lentigo solaris).	12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Secondary	Patient Complete Response 12 Weeks After PDT-2	Patient complete response (complete clearance of all treated lesions) assessed 12 weeks after PDT-2 (first PDT cycle). The PP set is the primary analysis set for the analysis of the secondary endpoint.	12 weeks after PDT-2 (=PDT cycle 1; please note: in this study 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Secondary	Cosmetic Outcome 12 Weeks After Last PDT (Including Patients With a Sum Score of 0 at Baseline)	Overall cosmetic outcome 12 weeks after last PDT is calculated as difference between 12 weeks after PDT sum score and baseline sum score of all skin quality assessments. Each of the below skin quality characteristics are assessed on a 4-point scale from 0 (none) to 3 (severe) by the investigator at baseline and 12 weeks after last PDT: Skin surface; Hyperpigmentation; Hypopigmentation; Mottled or irregular pigmentation; Degree of scarring; Atrophy; Cosmetic outcome categories are: Very good: 12 weeks sum score improved by at least 2 points compared to baseline; Good: 12 weeks sum score improved by 1 point compared to baseline; Satisfactory: 12 weeks sum score identical to the one at baseline; Unsatisfactory: 12 weeks sum score worsened by 1 point compared to baseline; Impaired: 12 weeks sum score worsened by at least 2 points compared to baseline	12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Secondary	Cosmetic Outcome 12 Weeks After the Last PDT (Including Patients With a Baseline Sum Score >1)	Overall cosmetic outcome 12 weeks after last PDT is calculated as difference between 12 weeks after PDT sum score and baseline sum score of all skin quality assessments. Each of the below skin quality characteristics are assessed on a 4-point scale from 0 (none) to 3 (severe) by the investigator at baseline and 12 weeks after last PDT: Skin surface; Hyperpigmentation; Hypopigmentation; Mottled or irregular pigmentation; Degree of scarring; Atrophy; Cosmetic outcome categories are: Very good: 12 weeks sum score improved by at least 2 points compared to baseline; Good: 12 weeks sum score improved by 1 point compared to baseline; Satisfactory: 12 weeks sum score identical to the one at baseline; Unsatisfactory: 12 weeks sum score worsened by 1 point compared to baseline; Impaired: 12 weeks sum score worsened by at least 2 points compared to baseline	12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

External Links

•   US National Library of Medicine National Institutes of Health